Humana (NYSE:HUM – Get Free Report) had its price objective dropped by research analysts at JPMorgan Chase & Co. from $593.00 to $575.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 13.90% from the company’s previous close.
A number of other equities research analysts have also issued reports on HUM. Royal Bank of Canada upped their target price on shares of Humana from $594.00 to $599.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Humana from $468.00 to $628.00 and gave the stock a “buy” rating in a research note on Monday, August 7th. Sanford C. Bernstein decreased their target price on shares of Humana from $599.00 to $579.00 in a report on Tuesday, October 10th. StockNews.com upgraded shares of Humana from a “buy” rating to a “strong-buy” rating in a report on Friday, November 3rd. Finally, TD Cowen decreased their price objective on Humana from $616.00 to $613.00 and set an “outperform” rating on the stock in a report on Tuesday, August 15th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Humana has an average rating of “Moderate Buy” and a consensus price target of $590.28.
View Our Latest Analysis on HUM
Humana Price Performance
HUM traded down $8.09 during midday trading on Friday, hitting $504.82. 305,774 shares of the company traded hands, compared to its average volume of 1,142,177. The company has a market capitalization of $62.15 billion, a price-to-earnings ratio of 20.93, a PEG ratio of 1.33 and a beta of 0.61. The business has a 50 day simple moving average of $496.41 and a two-hundred day simple moving average of $486.16. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.56. Humana has a 52-week low of $423.29 and a 52-week high of $558.04.
Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings data on Wednesday, November 1st. The insurance provider reported $7.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.15 by $0.63. The company had revenue of $26.42 billion for the quarter, compared to analysts’ expectations of $25.57 billion. Humana had a return on equity of 21.03% and a net margin of 2.95%. Humana’s revenue was up 15.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.88 EPS. On average, equities analysts forecast that Humana will post 28.28 earnings per share for the current fiscal year.
Institutional Trading of Humana
A number of large investors have recently bought and sold shares of HUM. Sunbelt Securities Inc. purchased a new position in Humana during the first quarter worth about $28,000. WFA of San Diego LLC acquired a new position in Humana during the second quarter worth about $29,000. Gradient Investments LLC increased its holdings in Humana by 50.0% in the second quarter. Gradient Investments LLC now owns 69 shares of the insurance provider’s stock valued at $31,000 after buying an additional 23 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Humana by 81.0% during the 2nd quarter. Larson Financial Group LLC now owns 76 shares of the insurance provider’s stock valued at $34,000 after acquiring an additional 34 shares during the period. Finally, Baystate Wealth Management LLC increased its stake in Humana by 84.1% in the 2nd quarter. Baystate Wealth Management LLC now owns 81 shares of the insurance provider’s stock valued at $37,000 after purchasing an additional 37 shares in the last quarter. Institutional investors and hedge funds own 91.86% of the company’s stock.
About Humana
(Get Free Report)
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humana, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Humana wasn’t on the list.
While Humana currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Source: marketbeat.com
Humana (NYSE:HUM – Get Free Report) had its price objective dropped by research analysts at JPMorgan Chase & Co. from $593.00 to $575.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 13.90% from the company’s previous close.
A number of other equities research analysts have also issued reports on HUM. Royal Bank of Canada upped their target price on shares of Humana from $594.00 to $599.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Humana from $468.00 to $628.00 and gave the stock a “buy” rating in a research note on Monday, August 7th. Sanford C. Bernstein decreased their target price on shares of Humana from $599.00 to $579.00 in a report on Tuesday, October 10th. StockNews.com upgraded shares of Humana from a “buy” rating to a “strong-buy” rating in a report on Friday, November 3rd. Finally, TD Cowen decreased their price objective on Humana from $616.00 to $613.00 and set an “outperform” rating on the stock in a report on Tuesday, August 15th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Humana has an average rating of “Moderate Buy” and a consensus price target of $590.28.
View Our Latest Analysis on HUM
Humana Price Performance
HUM traded down $8.09 during midday trading on Friday, hitting $504.82. 305,774 shares of the company traded hands, compared to its average volume of 1,142,177. The company has a market capitalization of $62.15 billion, a price-to-earnings ratio of 20.93, a PEG ratio of 1.33 and a beta of 0.61. The business has a 50 day simple moving average of $496.41 and a two-hundred day simple moving average of $486.16. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.56. Humana has a 52-week low of $423.29 and a 52-week high of $558.04.
Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings data on Wednesday, November 1st. The insurance provider reported $7.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.15 by $0.63. The company had revenue of $26.42 billion for the quarter, compared to analysts’ expectations of $25.57 billion. Humana had a return on equity of 21.03% and a net margin of 2.95%. Humana’s revenue was up 15.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.88 EPS. On average, equities analysts forecast that Humana will post 28.28 earnings per share for the current fiscal year.
Institutional Trading of Humana
A number of large investors have recently bought and sold shares of HUM. Sunbelt Securities Inc. purchased a new position in Humana during the first quarter worth about $28,000. WFA of San Diego LLC acquired a new position in Humana during the second quarter worth about $29,000. Gradient Investments LLC increased its holdings in Humana by 50.0% in the second quarter. Gradient Investments LLC now owns 69 shares of the insurance provider’s stock valued at $31,000 after buying an additional 23 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Humana by 81.0% during the 2nd quarter. Larson Financial Group LLC now owns 76 shares of the insurance provider’s stock valued at $34,000 after acquiring an additional 34 shares during the period. Finally, Baystate Wealth Management LLC increased its stake in Humana by 84.1% in the 2nd quarter. Baystate Wealth Management LLC now owns 81 shares of the insurance provider’s stock valued at $37,000 after purchasing an additional 37 shares in the last quarter. Institutional investors and hedge funds own 91.86% of the company’s stock.
About Humana
(Get Free Report)
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humana, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Humana wasn’t on the list.
While Humana currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Source: marketbeat.com
